MedCap acquires and develops profitable, market-leading niche companies in the Nordic life science industry that have the potential to grow internationally. The group conducts operations in two areas: MedTech and Specialty Pharma.
MedCap is an active and long-term owner, with independent subsidiaries operated under their own company names while upholding overall strategies and synergies. Companies that become part of the group gain access to resources that are difficult to create within smaller companies, including networks and active support where this strengthens the business. Governance is exercised principally through the boards of the owned companies, based on a clear allocation of mandates, values and corporate philosophy to provide the best possible conditions for profitability and growth.
During the fiscal year 1 January – 31 December 2019, the MedCap group exhibited annual net sales of SEK 757 million and EBITDA of SEK 140 million, and had more than 270 employees. The group is listed on the Small Cap list of Nasdaq Stockholm.